Internal Medicine, Hematology & Oncology · Fresno, CA
NPI
1417904020
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
7130 N Millbrook Ave
Fresno, CA, 93720
Phone (559) 326-1222
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
287,870 services
Medicare patients, 2024
870
Average age 74
Drug cost, 2024
$4.4M
1,728 prescriptions
Company payments, 2025
$1,673
From 28 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William J Jawien was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 65,700 times for 70 patients. In total William J Jawien billed 287,870 services in 199 codes, and Medicare paid $3.8M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-09.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 65,700 | 70 | $2.33 | $153K |
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 37,920 | 11 | $0.37 | $14K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 33,000 | 33 | $0.87 | $29K |
| J9299 Injection, nivolumab, 1 mg | Office | 23,040 | 15 | $24.60 | $567K |
| J1071 Injection, testosterone cypionate, 1 mg | Office | 12,050 | 16 | $0.02 | $246 |
| J0185 Injection, aprepitant, 1 mg | Office | 11,700 | 31 | $1.35 | $16K |
| J0897 Injection, denosumab, 1 mg | Office | 6,840 | 33 | $20.47 | $140K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,482 | 65 | $0.10 | $663 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 4,800 | 42 | $15.97 | $77K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 4,700 | 20 | $4.41 | $21K |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 1,950 | 19 | $51.97 | $101K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,916 | 66 | $0.09 | $172 |
| 85025 Blood Count | Office | 1,556 | 396 | $7.61 | $12K |
| 36415 Venipuncture Blood Collection | Office | 1,484 | 391 | $8.64 | $13K |
| 99214 Office E&M - Established | Office | 1,203 | 425 | $96.80 | $116K |
By year: 2022 $3.1M for 300,676 services; 2023 $4.8M for 379,209 services; 2024 $3.8M for 287,870 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,556 | 396 | $7.61 | $12K |
| 36415 Venipuncture Blood Collection | 1,484 | 391 | $8.64 | $13K |
| 80053 Clinical Chemistry | 1,026 | 348 | $10.34 | $11K |
| 83540 Clinical Chemistry | 433 | 194 | $6.33 | $2,739 |
| 83550 Clinical Chemistry | 432 | 194 | $8.53 | $3,686 |
| 82728 Clinical Chemistry | 431 | 194 | $13.30 | $5,731 |
| 80048 Clinical Chemistry | 260 | 122 | $8.29 | $2,155 |
| 83615 Clinical Chemistry | 152 | 45 | $5.92 | $900 |
| 82664 Immunoassay | 134 | 75 | $59.82 | $8,016 |
| 82378 Clinical Chemistry | 124 | 33 | $18.58 | $2,304 |
Medicare prescription drug claims, 2024
In 2024, the drug William J Jawien prescribed most often to Medicare patients was Anastrozole, with 173 prescriptions and refills. In total William J Jawien wrote 1,728 Medicare prescriptions that cost $4.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 173 | 276 | 31 | $3,080 |
| Clinimix E Amino Ac 8 %/D14w/Electrolytes | 87 | 87 | Under 11 | $27K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 79 | 80 | 23 | $1,849 |
| Warfarin Sodium Generic | 67 | 108 | Under 11 | $725 |
| Ondansetron Odt Ondansetron | 64 | 71 | 24 | $679 |
| Eliquis Apixaban | 59 | 75 | Under 11 | $44K |
| Levothyroxine Sodium Generic | 54 | 100 | 12 | $328 |
| Prednisone Generic | 54 | 55 | 17 | $257 |
| Hydroxyurea Generic | 52 | 82 | Under 11 | $700 |
| Prochlorperazine Maleate Generic | 49 | 55 | 24 | $904 |
| Lorazepam Generic | 43 | 43 | 25 | $170 |
| Jakafi Ruxolitinib Phosphate | 42 | 42 | Under 11 | $725K |
| Lenalidomide Generic | 38 | 38 | Under 11 | $575K |
| Ibrance Palbociclib | 30 | 30 | Under 11 | $464K |
| Dexamethasone Generic | 26 | 26 | Under 11 | $197 |
Brand drugs: 496 claims; generic drugs: 1,232 claims; opioid claims: 158.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William J Jawien $1,673 ($1,673 in general payments such as food, travel and fees) from 28 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $267.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $267 |
| Daiichi Sankyo Inc. 4568.T | 10 | $138 |
| Abbvie Inc. ABBV | 6 | $135 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $126 |
| SpringWorks Therapeutics, Inc. | 4 | $116 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 3 | $90.33 |
| Celgene Corporation BMY | 4 | $75.8 |
| Merck Sharp & Dohme LLC MRK | 3 | $64.96 |
| PharmaEssentia USA Corporation 6446.TW | 3 | $61.01 |
| Exelixis Inc. EXEL | 3 | $58.99 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.